Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review
Reported Earlier, Mesoblast Secures BLA Filing Number For Rexlemestrocel-L, Backed By Orphan Drug And RMAT Designations For Priority Review Eligibility
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.